Time to deterioration in cancer randomized clinical trials for patient-reported outcomes data: a systematic review
出版年份 2019 全文链接
标题
Time to deterioration in cancer randomized clinical trials for patient-reported outcomes data: a systematic review
作者
关键词
-
出版物
QUALITY OF LIFE RESEARCH
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2019-11-27
DOI
10.1007/s11136-019-02367-7
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2
- (2018) Sunil Verma et al. BREAST CANCER RESEARCH AND TREATMENT
- Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based Chemotherapy
- (2018) Enriqueta Felip et al. Clinical Lung Cancer
- Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer
- (2018) David J. Vaughn et al. JOURNAL OF CLINICAL ONCOLOGY
- Patient-Reported Symptoms and Impact of Treatment With Osimertinib Versus Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The AURA3 Trial
- (2018) Chee Khoon Lee et al. JOURNAL OF CLINICAL ONCOLOGY
- Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial
- (2018) David Cella et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of Nivolumab versus Docetaxel on Health-Related Quality of Life and Symptoms in Patients with Advanced Squamous Non–Small Cell Lung Cancer: Results from the CheckMate 017 Study
- (2018) Martin Reck et al. Journal of Thoracic Oncology
- Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial
- (2018) Kim N Chi et al. LANCET ONCOLOGY
- Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma
- (2018) Martin J. B. Taphoorn et al. JAMA Oncology
- Health-related quality of life results from the PRODIGE 5/ACCORD 17 randomised trial of FOLFOX versus fluorouracil–cisplatin regimen in oesophageal cancer
- (2017) C. Bascoul-Mollevi et al. EUROPEAN JOURNAL OF CANCER
- Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma
- (2017) Teresa M. Petrella et al. EUROPEAN JOURNAL OF CANCER
- Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Marianne E Pavel et al. LANCET ONCOLOGY
- Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial
- (2017) Yung-Jue Bang et al. LANCET ONCOLOGY
- Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial
- (2017) Kevin J Harrington et al. LANCET ONCOLOGY
- Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial
- (2017) Julie R Brahmer et al. LANCET ONCOLOGY
- Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study
- (2016) G. V. Long et al. ANNALS OF ONCOLOGY
- Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma
- (2016) S.-E. Al-Batran et al. ANNALS OF ONCOLOGY
- Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial
- (2016) N. Harbeck et al. ANNALS OF ONCOLOGY
- First-Line Pemetrexed Plus Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in East Asian Never-Smoker Patients With Locally Advanced or Metastatic Nonsquamous Non–Small-cell Lung Cancer: Quality of Life Results From a Randomized Phase III Trial
- (2016) Mark Boye et al. Clinical Lung Cancer
- Health-related quality of life in elderly patients with advanced non-small cell lung cancer comparing carboplatin and weekly paclitaxel doublet chemotherapy with monotherapy
- (2016) Frédéric Fiteni et al. EUROPEAN RESPIRATORY JOURNAL
- PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy
- (2016) Sharlene Gill et al. JOURNAL OF CLINICAL ONCOLOGY
- Statistical Challenges in the Analysis of Health-Related Quality of Life in Cancer Clinical Trials
- (2016) Franck Bonnetain et al. JOURNAL OF CLINICAL ONCOLOGY
- Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards
- (2016) Andrew Bottomley et al. LANCET ONCOLOGY
- Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy
- (2016) Maurice Pérol et al. LUNG CANCER
- Time to Definitive Health-Related Quality of Life Score Deterioration in Patients with Resectable Metastatic Colorectal Cancer Treated with FOLFOX4 versus Sequential Dose-Dense FOLFOX7 followed by FOLFIRI: The MIROX Randomized Phase III Trial
- (2016) Zeinab Hamidou et al. PLoS One
- Long-term health status as measured by EQ-5D among patients with metastatic breast cancer: comparison of first-line oral S-1 and taxane therapies in the randomized phase III SELECT BC trial
- (2016) T. Shiroiwa et al. QUALITY OF LIFE RESEARCH
- Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial
- (2016) Aaron Vinik et al. Targeted Oncology
- Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial
- (2015) Javier Cortes et al. BREAST CANCER RESEARCH AND TREATMENT
- Quality of patient-reported outcome reporting across cancer randomized controlled trials according to the CONSORT patient-reported outcome extension: A pooled analysis of 557 trials
- (2015) Fabio Efficace et al. CANCER
- Analysis of patient-reported outcomes from the LUME-Lung 1 trial: A randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer
- (2015) Silvia Novello et al. EUROPEAN JOURNAL OF CANCER
- Health-related quality-of-life as co-primary endpoint in randomized clinical trials in oncology
- (2015) Frédéric Fiteni et al. Expert Review of Anticancer Therapy
- Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma
- (2015) Martin J.B. Taphoorn et al. JOURNAL OF CLINICAL ONCOLOGY
- Symptom and Quality of Life Improvement in LUX-Lung 6: An Open-Label Phase III Study of Afatinib Versus Cisplatin/Gemcitabine in Asian Patients With EGFR Mutation-Positive Advanced Non–small-cell Lung Cancer
- (2015) Sarayut L Geater et al. Journal of Thoracic Oncology
- Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial
- (2015) Fred Saad et al. LANCET ONCOLOGY
- Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial
- (2015) Jean-Pascal H Machiels et al. LANCET ONCOLOGY
- Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial
- (2015) Yohann Loriot et al. LANCET ONCOLOGY
- Patient-reported outcomes as end points and outcome indicators in solid tumours
- (2015) Angeles A. Secord et al. Nature Reviews Clinical Oncology
- Axitinib versus sorafenib as a second-line therapy in Asian patients with metastatic renal cell carcinoma: results from a randomized registrational study
- (2015) Vardit Dror et al. OncoTargets and Therapy
- QoL analyses from INFORM study, a phase III study of gefitinib versus placebo as maintenance therapy in advanced NSCLC
- (2015) Yun-Peng Yang et al. Scientific Reports
- Prospective, Randomized, Multicenter, Phase III Study of Fluorouracil, Leucovorin, and Irinotecan Versus Epirubicin, Cisplatin, and Capecitabine in Advanced Gastric Adenocarcinoma: A French Intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) Study
- (2014) Rosine Guimbaud et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial
- (2014) Karim Fizazi et al. LANCET ONCOLOGY
- Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial
- (2014) Peter M Ellis et al. LANCET ONCOLOGY
- Quality of Life in the Trastuzumab for Gastric Cancer Trial
- (2014) Taroh Satoh et al. ONCOLOGIST
- Endpoints in cancer clinical trials
- (2014) F. Fiteni et al. Journal of Visceral Surgery
- Time to health-related quality of life score deterioration as a modality of longitudinal analysis for health-related quality of life studies in oncology: do we need RECIST for quality of life to achieve standardization?
- (2013) Amélie Anota et al. QUALITY OF LIFE RESEARCH
- Time to Deterioration in Quality of Life Score as a Modality of Longitudinal Analysis in Patients with Breast Cancer
- (2011) Z. Hamidou et al. ONCOLOGIST
- Time until definitive quality of life score deterioration as a means of longitudinal analysis for treatment trials in patients with metastatic pancreatic adenocarcinoma
- (2010) Franck Bonnetain et al. EUROPEAN JOURNAL OF CANCER
- Survival End Point Reporting in Randomized Cancer Clinical Trials: A Review of Major Journals
- (2008) Simone Mathoulin-Pelissier et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now